Skip to Main Content


Skip Nav Destination

Tumor Suppressor PLK2 May Serve as a Biomarker in Triple-Negative Breast Cancer for Improved Response to PLK1 Therapeutics

Cancer Research Communications (2021) 1 (3): 178–193.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal